Michael Doe

To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html                             Key Inclusions A detailed assessment of the current market landscape of light activated therapies, with respect to current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved), type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy), therapeutic area (oncological disorders (solid tumor), dental disorders, skin disorders,  oncological disorders (hematological cancer) and others), type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride), type of light (red light, blue light, ... Continue reading →

During our study, we were able to identify close to 500 players that are engaged in offering pharmaceutical contract manufacturing services. It is worth mentioning, most of the players (174) engaged in this domain offer contract manufacturing services for FDF / fill-finish operations, followed by those offering services for both API and FDF / fill-finish development (144). To Request for Sample report - https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html As can be observed in the figure, the pharmaceutical market is currently dominated by the presence of large and very large players (47%), followed by mid-sized firms (42%) and small companies (11%). Notable examples of well-established players engaged in this domain include (large and very large companies, in alphabetical order) Alembic Pharmaceutical, Angelini Pharma, Divi’s Laboratories, Fresenius Kabi and Lubrizol Life Sciences.   It is worth highlighting that, most ... Continue reading →

Primary packaging, such as vials, syringes, and cartridges, and their affiliated closures, play a vital role in ensuring the stability, and sterility, and thereby, the overall quality, efficacy and safety of a drug product. Moreover, the packaging bears the product label, which provides information related to the drug and, in certain cases, dosing instructions. Pharmaceutical packaging is typically carried out under controlled conditions; specifically, for therapeutics that are designed for parenteral administration, fill / finish is carried out in sterile and aseptic environments. It is also crucial for innovators (or packaging service providers) to choose the appropriate, high quality primary packaging for their respective products; this is because the packaging material is in direct contact with the drug / therapy. Building and maintaining the necessary expertise and infrastructure to support pharmacological fill / finish is a capital-intensive ordeal. Further, the growing ... Continue reading →

Over time, important advances in diagnosis and the development of versatile treatment options have translated into tangible improvements in the overall survival of lung cancer patients; several targeted therapies are being developed against squamous NSCLCs   Roots Analysis is pleased to announce the publication of its recent study, titled, “Squamous Non-small Cell Lung Cancer Market, 2021-2031.”   The report features an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities. In addition to other elements, the study includes: A detailed assessment of the therapeutic ... Continue reading →

Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications   London   Roots Analysis has announced the addition of “Vascular Disrupting Agents Market, 2021-2030” report to its list of offerings.   Despite multiple cancer treatment options, there is an evident unmet need for anti-cancer therapies with better efficacy and less toxicity. The vascular disrupting agents, which target the established tumor vasculature and disrupt blood flow to cancerous tissue, have garnered considerable interest as a novel anticancer therapeutic modality.    To order this 290+ page report, which features 110+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html   Key Market Insights   Currently, more than 120 vascular disrupting agents are in the development pipeline Around 50% of the vascular disrupting ... Continue reading →

Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments in this industry   Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of light activated therapies and drug developers engaged in this domain. Detailed profiles of marketed and late stage (phase III) clinical products. An in-depth analysis of completed, ongoing and planned clinical studies ... Continue reading →

The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy   London   Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings.   Presently, there is no cure for PSP and the effectiveness of prescribed generic medications and non-drug therapies to improve the quality of life in patients, is limited. The high unmet patient need and rising caregiver burden has inspired several players to focus their efforts on the development of therapies to control the progression of PSP or manage its symptoms. Consequently, multiple orphan designated drugs, currently in phase II of development, are anticipated to enter the market in the next 3-6 years.   To order this 100+ page report, which features ... Continue reading →

Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria   Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.   Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition ... Continue reading →

Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products   London   Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.   Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth ... Continue reading →

The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy   London   Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings.   Presently, there is no cure for PSP and the effectiveness of prescribed generic medications and non-drug therapies to improve the quality of life in patients, is limited. The high unmet patient need and rising caregiver burden has inspired several players to focus their efforts on the development of therapies to control the progression of PSP or manage its symptoms. Consequently, multiple orphan designated drugs, currently in phase II of development, are anticipated to enter the market in the next 3-6 years.   To order this 100+ page report, which features ... Continue reading →

Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria   Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.   Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition ... Continue reading →

Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products   London   Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.   Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth ... Continue reading →

Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world   Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”   The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features: A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).  A detailed landscape ... Continue reading →

The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the inherently complex neurodegenerative disease   Roots Analysis has announced the addition of “Alzheimer's Disease Market (2nd Edition), 2021-2031” report to its list of offerings.   Limited treatment options and unmet needs are the key drivers of research activity in this domain. Several industry and non-industry players are presently engaged in developing various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief. Moreover, multiple venture capital firms and other strategic investors have been supporting the research related initiatives of various start-ups. Driven by a rich development pipeline and the efforts of various stakeholders, the market is anticipated to grow at a significant pace in the ... Continue reading →

Polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors   London   Roots Analysis has announced the addition of “Polycystic Ovary Syndrome Market, 2021-2031” report to its list of offerings.   Currently, there is no cure for polycystic ovary syndrome (PCOS / PCOD), however the affiliated symptoms can be treated using a combination of different types of medications, including insulin-sensitizing agents, oral contraceptives, anti-androgens and anti-obesity drugs. The research activities, including clinical investigations in this domain are being driven by both industry and non-industry players.   To order this 90+ page report, which features 70+ figures, please visit https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-market.html ... Continue reading →

Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.   Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings.   The report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes: A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services An insightful geographical benchmarking of the capabilities of companies of various sizes, ... Continue reading →

  The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research   London   Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.   Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this - https://www.rootsanalysis. ... Continue reading →

To order this detailed 320+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html   Key Inclusions A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer. Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In ... Continue reading →

Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions   Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.  A detailed analysis of more than 590 completed, ongoing and planned clinical studies ... Continue reading →

Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.   Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings.   The report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes: A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services An insightful geographical benchmarking of the capabilities of companies of various sizes, ... Continue reading →